GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » EV-to-FCF

Artgen Biotech PJSC (MIC:ABIO) EV-to-FCF : 51.03 (As of May. 25, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Artgen Biotech PJSC's Enterprise Value is ₽6,192 Mil. Artgen Biotech PJSC's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was ₽121 Mil. Therefore, Artgen Biotech PJSC's EV-to-FCF for today is 51.03.

The historical rank and industry rank for Artgen Biotech PJSC's EV-to-FCF or its related term are showing as below:

MIC:ABIO' s EV-to-FCF Range Over the Past 10 Years
Min: -333.04   Med: -4.14   Max: 369.45
Current: 51.03

During the past 13 years, the highest EV-to-FCF of Artgen Biotech PJSC was 369.45. The lowest was -333.04. And the median was -4.14.

MIC:ABIO's EV-to-FCF is ranked worse than
79.84% of 372 companies
in the Biotechnology industry
Industry Median: 8.36 vs MIC:ABIO: 51.03

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Artgen Biotech PJSC's stock price is ₽103.10. Artgen Biotech PJSC's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was ₽0.580. Therefore, Artgen Biotech PJSC's PE Ratio for today is 177.76.


Artgen Biotech PJSC EV-to-FCF Historical Data

The historical data trend for Artgen Biotech PJSC's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artgen Biotech PJSC EV-to-FCF Chart

Artgen Biotech PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -53.21 155.21 -108.52 71.03 69.25

Artgen Biotech PJSC Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 71.03 - 69.25 -

Competitive Comparison of Artgen Biotech PJSC's EV-to-FCF

For the Biotechnology subindustry, Artgen Biotech PJSC's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artgen Biotech PJSC's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artgen Biotech PJSC's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Artgen Biotech PJSC's EV-to-FCF falls into.



Artgen Biotech PJSC EV-to-FCF Calculation

Artgen Biotech PJSC's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6192.044/121.343
=51.03

Artgen Biotech PJSC's current Enterprise Value is ₽6,192 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Artgen Biotech PJSC's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was ₽121 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Artgen Biotech PJSC  (MIC:ABIO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Artgen Biotech PJSC's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=103.10/0.580
=177.76

Artgen Biotech PJSC's share price for today is ₽103.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Artgen Biotech PJSC's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was ₽0.580.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Artgen Biotech PJSC EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Artgen Biotech PJSC's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Artgen Biotech PJSC (MIC:ABIO) Business Description

Traded in Other Exchanges
N/A
Address
Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.